The longevity biotechnology company NOVOS has released results from a randomized, double blind, placebo-controlled clinical trial of its flagship supplement NOVOS Core. This venture demonstrates statistically significant improvements in three distinct cardiovascular biomarkers associated with healthy aging — endothelial function, arterial flexibility, and systolic blood pressure.
The study relied on adults aged 40 and older without diagnosed heart disease and lasted over six months. The researchers concluded that individuals using NOVOS Core experienced a 2.9% improvement in flow-mediated dilation shortly after the first dose and sustained that benefit for half a year, while the placebo group showed no meaningful change. The improvement in arterial function was comparable to what published studies have shown from sustained high-intensity interval training, the reduction in pulse wave velocity matched or exceeded results from Mediterranean diet interventions and significant weight loss, and the 6.1 millimetres of mercury drop in systolic blood pressure occurred even though participants already had readings in the normal range.
Image Credit: NOVOS
